# Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Source: https://onco.cc/trials/nct00822393/  
OnCo record `nct00822393` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Busulfan and Treosulfan in Acute myeloid leukaemia, run by medac GmbH, completed.

## Summary

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) is a phase 3 interventional study registered as NCT00822393 by medac GmbH, with 570 participants recorded, started 2008-11-24 and reaching its primary completion in 2018-01-25. Interventions recorded: Busulfan, Treosulfan. Conditions recorded: Acute Myeloid Leukemia, Myelodysplastic Syndrome.

Linked to the drug Treosulfan because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00822393
- Phase: 3
- Setting: Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
- Sponsor: medac GmbH
- Enrolled: 570

## Sources

- ClinicalTrials.gov NCT00822393: https://clinicaltrials.gov/study/NCT00822393

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Busulfan](https://onco.cc/drugs/busulfan/), [Treosulfan](https://onco.cc/drugs/treosulfan/)
- companies: [medac](https://onco.cc/companies/medac/)

---
JSON: https://onco.cc/api/v1/entities/nct00822393.json